IXICO plc - Update for first half of year ending 31 March 2019
("IXICO" or the "Company")
Trading update for the first half of financial year ending
On track to deliver robust revenue growth from
Strong closing cash balance of
· Reported revenues expected to be
· Strong closing cash balance of
· Order book* stood at
On the basis of the revenues for the first half, the Company remains confident that revenues for the full year to
The Company's first half results will be released on
"Our data analytics focused strategy of deploying our proprietary AI algorithms in both current and adjacent therapeutic areas continues to drive market penetration and we are well capitalised to fund further organic growth initiatives to provide valuable new technology solutions to our clients. Investments in our technology platform and our staff are delivering operational efficiencies and cost-effective solutions so that we continue to benefit from increased demand for our specialist data analytics services."
* Order book is contracted but unrecognised revenue
For further information please contact:
| || |
+44 (0) 20 3763 7498
| || |
Cenkos Securities PLC (Nominated adviser and sole broker)
+44 (0) 20 7397 8900
| || |
Michael F Johnson /
+44 (0) 203 950 9144
Mary Clark /
IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.
IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.
More information is available on www.IXICO.com
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).
This information is provided by RNS, the news service of the
Quick facts: IXICO PLC
Market Cap: £32.42 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE